The Contraceptives Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, Competitive Landscape, etc. According to the report the Contraceptive Market is estimated to be 21.50 USD Billion in 2016 and predicted to rise to 29.60 USD Billion by the end of 2021 with a CAGR of 6.60 %. Based on drug type the market is segmented into Contraceptive pills, Topical contraceptives, Contraceptive injectable, Others (contraceptive gels, jellies and creams). Based on medical devices the market is segmented into Male contraceptive devices (Condoms), Female contraceptive devices, Contraceptive Sponges, Contraceptive Diaphragms, Contraceptive Patches, Sub-dermal Contraceptive Implants, Non-Surgical Permanent Contraceptive Devices, and Contraceptive Vaginal Rings. Based on end users the market is segmented into Hospitals, Home care, Clinics and Ambulatory Surgical Centers. Further the market is also geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa.
Contraception is a prevention of pregnancy by interfering with normal process of fertilization, ovulation and implantation through the use of drugs, barriers, medical devices, surgical techniques. They are the drugs which will also inhibit sexually transmitted diseases. Contraception methods can be permanent or temporary that are available for both men and women. Permanent methods include tubal occlusion or hysteroscopy and vasectomy. Temporary methods are of two types i.e., hormonal and non-hormonal. Vaginal implants, Male and female condoms, subdermal implants, sponges, IUDs and diaphragms are important devices that accounts for the largest share in the market in terms of revenue. This is attributed to growing awareness about STD (Sexually transmitted disease) and the efficiency of condoms to inhibit the infections, including HIV.
The Major factors that attribute to the growth of the Market are by growing development of effective female contraceptive devices and drugs, advancement in technologies, increasing initiatives from government and NGO to promote contraceptives. Restraints the growth of the market are the side effects associated with the use of contraceptive devices and drugs, rising prevalence of infertility.
Among the drug type, Contraceptive Pills is projected to account largest share owing to a significantly increasing awareness levels, large consumer base, as well as government initiatives to address the unmet needs of the women in the reproductive age. Condoms are recognized to be the most profitable segment in the overall contraceptives market, due to rising number of condom programs to increase user awareness levels which focuses on its effectiveness in preventing sexually transmitted diseases (STDs). Intrauterine device segment is also slated to grab significant market share over the forecast period owing to, high usage rates associated with the existing IUDs.
North America is expected to have largest share in the market followed by Europe, Asia-Pacific, Latin America, Middle-East and Africa. This market share is attributed due to increasing incidences of abortion, rising patient awareness in the region and growing population of women within the susceptible age group of 15-44 years.
Some of the major companies influencing the Contraceptive market, by their products and services include Bayer HealthCare AG, Teva Pharmaceutical Industries Limited, Medisafe Distribution Inc, Pace Pharmaceuticals Inc., Medicines360, Church & Dwight, Co., Inc., Actavis, Inc., CooperSurgical, Inc., Merck & Co., Inc., Reckitt Benckiser plc, Mayer Laboratories, Inc., and Pfizer, Inc.
Browse through the full report at â€œhttp://www.marketdataforecast.com/market-reports/global-contraceptives-market-1228/â€ and checkout our recent reports in the Medical Devices category at â€œhttp://www.marketdataforecast.com/research-reports/healthcare/medical-devices-2/â€. For more insights and up-to-date industry news donâ€™t forget subscribing to our newsletters.